Exploring the Impact of Dual Incretin Therapy on Glycemic Control and Weight Management in Type 2 Diabetes

Almoeiz Y. Hammad

Published on: 2024-12-15

Abstract

Type 2 diabetes (T2D) is a widespread chronic condition that affects millions of people globally, and it is primarily driven by insulin resistance and dysfunctional glucose regulation. For years, treatment strategies have focused on controlling blood sugar levels and managing weight, but often without achieving optimal results in both areas simultaneously. However, emerging therapies that target the body's incretin system specifically by combining Glucagon-Like Peptide-1 (GLP-1) receptor agonists with Glucose-dependent Insulinotropic Peptide (GIP) receptor agonists, or Dipeptidyl Peptidase-4 (DPP-4) inhibitors are showing great promise. These dual incretin therapies aim to enhance both glucose control and weight loss, offering a more holistic approach to managing T2D. This study examines the effects of dual incretin therapy on key outcomes like glycemic control, weight reduction, and safety in T2D patients. The findings suggest that dual incretin therapy significantly lowers HbA1c levels, promotes weight loss, and presents a favorable safety profile, especially when compared to traditional monotherapies.